Prot #NU12G11: The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date5/6/1310/31/21

Funding

  • National Comprehensive Cancer Network (Prot #NU12G11)
  • AVEO Pharmaceuticals, Inc. (Prot #NU12G11)